Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report

Table 1 Time line showing the clinical course of the patient

Period 2008-09	Event	HCV RNA IU/mL	WBC×103/μL	ANC/μL	Hb g/dL	Platelets×103/μL	ALT IU/L	BT mg/dL	TSH IU/mL	IFN dose/wk	RBV dose/d
Early December	Start of HCV treatment	4 275 000	5.6	3600	15.9	NCa	66	0.7	1.55	180 mcg	1000 mg
Early January	Platelets decreased	309 230	5.0	2300	14.5	31	57	1.0	NA	135 mcg	No change
Late January	Start of neurological symptoms	18 880	3.9	1400	12.7	45	38	0.8	NA	Treatment held
Mid February	Worsening of symptoms	NA	6.4	4000	15.1	61	59	0.6	1.92	Treatment on hold
April	F/U visitb improvement in symptoms	499 660	7.2	4400	15.8	94	61	0.6	NA	Treatment on hold

ANC: Absolute neutrophilic count; Hb: Hemoglobin; BT: Bilirubin total; IFN: Interferon; RBV: Ribavirin; F/U: follow-up; NA: Not available; NC: Not calculated.

^aDue to clumping of platelets, result was not recorded. Later on repeating, platelets were found to be 55 × 10³/μL;

^bLast follow up to hepatology clinic but patient is being followed up regularly by the neurologist in clinic and by hepatology staff.